Spike Protein News and Research

RSS

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Researchers in the U.S. have demonstrated how dominant energetic landscape mappings or glue points, along with sequence alignment information can potentially identify key residue mutations and spike protein deletions tied with emerging variants.

12 Feb 2021

New SARS-CoV-2 variant found in newborn child with seizures in the United States

Researchers at a hospital in Washington D.C. found a new mutant strain of the virus in a neonatal patient with high viral loads. According to the authors, this strain could be spreading in the United States mid-Atlantic population and needs monitoring.

11 Feb 2021

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

Researchers in the United States who tracked the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient found that convalescent plasma therapy was associated with the emergence of viral variants that were less susceptible to neutralizing antibodies.

11 Feb 2021

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, according to a study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania.

10 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

A recent study conducted by US scientists has demonstrated that the distribution of local topological free energy along the spike protein domains of SARS-CoV-2 is associated with their activity in protein rearrangement.

10 Feb 2021

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.

10 Feb 2021

Scientists urge health agencies to invest in COVID-19 vaccine development to prevent next pandemic

As new COVID-19 variants begin to throw vaccine efficacy in question, two leading scientists are calling for health agencies to invest in the development of vaccines that would be broadly effective against many different variants and strains of potential pandemic viruses.

10 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers describe the impending rise to dominance of the B.1.1.7 (UK) variant in the US. Understanding this development will help to shape preventive action to reduce the infection and mortality rates.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

A precursor to remdesivir shows therapeutic potential for COVID-19

A new study points to the potential to use the remdesivir precursor, GS-441524, as a treatment choice for COVID-19.

9 Feb 2021

One-dose SARS-CoV-2 vaccine policy may lead to antigenic evolution, study finds

In a new study, published on the pre-print server medRxiv, an international team of researchers found that a one-dose policy may increase the potential for antigenic evolution. The study revealed that focusing on one dose may decrease infections in the short term, but longer-term outcomes rely on this immune strength.

8 Feb 2021

Spike Protein News and Research

New mouse model of SARS-CoV-2 infection reflects features of human infection

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

New SARS-CoV-2 variant found in newborn child with seizures in the United States

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Study shows local topological free energy as determinant of SARS-CoV-2 spike stability

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Scientists urge health agencies to invest in COVID-19 vaccine development to prevent next pandemic

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

Emergence and transmission of UK SARS-CoV-2 variant in the US

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A precursor to remdesivir shows therapeutic potential for COVID-19

One-dose SARS-CoV-2 vaccine policy may lead to antigenic evolution, study finds

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News